Pain, PostoperativePhase 4NCT02601651
Effect of Perioperative Intravenous Lidocaine on Opioid Consumption and Pain After Laparoscopic Totally Extraperitoneal Inguinal Hernioplasty
A Phase 4 study testing Lidocaine and Normal saline in people with Pain, Postoperative, run by B.P. Koirala Institute of Health Sciences at 1 site in Nepal.
Trial summary
The primary objectives of this study is to access the effect of perioperative lidocaine infusion on total morphine requirement during the first 24 h postoperatively in patients who underwent laparoscopic totally extraperitoneal inguinal hernioplasty. Read more about this study
- Who is it for?
- Ages 18 to 65 years, men only
- Conditions the study is for
- Pain, Postoperative
- What is being tested?
- Lidocaine and Normal saline
- Type of treatment
- Injection or infusion
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 64 participants
- Where
- 1 siteNepal
- Study dates
- Dec 2015to Mar 2017
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male patients with American Society of Anaesthesiologists physical status (ASA PS) I and II of age 18 to 65 years
- Patients undergoing laparoscopic totally extraperitoneal repair for unilateral/bilateral inguinal hernia.
Who cannot join
- Refusal to give consent.
- ASA physical status III or more.
- Inability to comprehend pain assessment score or severe mental impairment
- Patient who weighed < 40 kg or >100 kg
- Severe underlying cardiac rhythm disorder
- Renal or hepatic disease
Show all 9Show fewer
- Allergic to local anaesthetics
- Epilepsy
- Patients on regular analgesics or anti-arrhythmic drugs
Trial locations and contacts
1 site in 1 country.
About this study
The primary objectives of this study is to access the effect of perioperative lidocaine infusion on total morphine requirement during the first 24 h postoperatively in patients who underwent laparoscopic totally extraperitoneal inguinal hernioplasty.
Read the detailed description
The use of intravenous lidocaine can be considered as a multimodal approach to pain relief. This method of analgesia has been associated with reductions in post-operative pain, analgesic consumption, nausea, vomiting and length of hospital stay in various surgeries (abdominal, spinal, thoracic surgery) including laparoscopic procedure .The primary reason for delayed patient recovery and longer hospital stays after surgery is postoperative pain and ileus .Opioids are the mainstay drug to treat pain in the postoperative period. However, nausea, vomiting, postoperative ileus and further delay in patient recovery will be exacerbated by opioid administration.
the higher inflammatory response is observed in the early postoperative phase following TEP surgery compared to the conventional shouldice repair. Therefore, laparoscopic repair of inguinal hernia should not be seen as less traumatic than the conventional approach.
Low-dose IV lidocaine (typically 1.5-3 mg/kg/h) is easy to administer, has well-established analgesic, anti-hyperalgesic, and anti-inflammatory effects, and excellent safety record . Because postoperative pain is to a large extent an inflammatory phenomenon, administration of systemic local anesthetics, which have inflammatory modulatory properties, could significantly reduce pain and therefore allow more rapid discharge. In addition, intravenous lidocaine is an effective modality for treating visceral pain.
Objectives
Primary : To access the effect of perioperative lidocaine infusion on total morphine requirement during the first 24 h postoperatively in patients who underwent laparoscopic TEP for inguinal hernioplasty
Secondary:
- Postoperative NRS Scores at rest and during movement (i.e. deep breathing, coughing) (at PACU, 2, 4, 6, 8, 12 and 24h)
- Time to first perception of pain in the postoperative period
- Incidence of post operative nausea and vomiting, shivering, and tinnitus during the first 24h
- Quality of Recovery based on QoR-40 questionnaire at 24 h of the surgery.
- Patient satisfaction at 24 h of the surgery.
- Incidence of Chronic pain after TEP Repair at 3 months.
RESEARCH HYPOTHESIS Perioperative intravenous lidocaine administration will not decrease opioid requirements and pain scores during the first 24 h after TEP for inguinal hernioplasty.
METHODOLOGY Written informed consent will be taken for the procedure from all the patients. A total of 64 male subjects of ASA PS I and II undergoing laparoscopic totally extraperitoneal inguinal hernia repair will be enrolled in the study. The study will be carried out according to the principles of the Declaration of Helsinki and following CONSORT guidelines.
After preoperative evaluation, all of the patients will be premedicated with oral diazepam (0.1-0.2 mg/kg; not exceeding > 10 mg) at the night before and 2 hour before surgery.In order to assess pain patients will be familiarized about the use of the Numeric Pain Rating Scale (NRS) (0-10 cm) where 0 is no pain and 10 is the worst imaginable excruciating pain. They will also be informed that they will be asked about the intensity of the pain using NRS score and the site of pain (incisional pain or groin pain) in the postoperative period.
During the study, both the patient and the investigator observing the outcome will be blinded about the assignment of patient group. In the preoperative holding area, the patients will be randomly assigned into any of two groups using computer generated random number. Details of group assignment and case number will be kept in a set of sealed opaque envelope. The anesthesia staff will open the envelope and prepare the intravenous solutions accordingly. The attending anesthesiologist who is unaware of the group allocated will follow the standard general anaesthesia protocol during the study.
In the operating room standard monitoring device will be attached to monitor and baseline heart rate, non-invasive blood pressure and oxygen saturation will be recorded. A peripheral vein will be cannulated for administration of IV fluid with 18 G cannula. Preoxygenation will be done with 100% oxygen for 3 min. Induction will be done with IV fentanyl 1.5 μg/kg, propofol 2-2.5 mg/kg till cessation of verbal response and tracheal intubation facilitated with vecuronium 0.1mg/kg IV.
At induction, lidocaine group (A group) patients will receive 1.5 mg/kg of lidocaine (Loxicard®, Neon pharmaceuticals, India) IV bolus followed by infusion of 2 mg/kg/h. The Normal Saline group (B group) will receive same volume IV bolus at induction followed by continuous infusion until the tracheal extubation.
Patients in both the group will receive preincisional infiltration in three trocar sites with 6 ml of 0.25% bupivacaine.
In all groups, anesthesia will be maintained with oxygen and isoflurane, adjusting the end-tidal concentration of isoflurane to maintain Mean Arterial Pressure(MAP) within 20% of baseline. IV fentanyl 0.5 μg/kg will be supplemented intraoperatively if MAP and heart rate increase by 20% from the baseline after ensuring adequate end tidal concentration of isoflurane ,muscle relaxation and targeted range of ETCO2. After observing curare notch in capnograph, supplemental vecuronium IV bolus doses will be given . Paracetamol 1 gm IV infusion will be started after induction and given over 15 min. Any episode of intraoperative hypotension (MAP lower than 65 mmHg) and bradycardia (heart rate < 50 bpm) will be treated with ephedrine 5 mg and atropine 0.4 mg IV respectively.
Standardized surgical procedure for the hernia as described for endoscopic TEP for inguinal hernia repair will be followed. Ketorolac 30 mg IV will be given at the end of surgery and continued at 8 h intervals postoperatively. On the completion of surgery, residual neuromuscular block will be reversed with neostigmine 0.05 mg/kg IV and glycopyrrolate 0.01 mg/kg IV. Following successful tracheal extubation, infusion of the lidocaine or saline will be stopped and the patient will be transferred to the postanesthesia care unit (PACU).
Postoperative Care and observation On arrival to the PACU, non-invasive blood pressure, heart rate, respiration, primary and secondary outcome variables will be monitored by the blinded investigator. Pain including its site will be assessed at rest and on deep breathing or coughing by NRS every 15 mins for the first 1 h and then at 2, 4, 6, 8, 12 and 24 h after surgery. If the NRS for pain is more than 3 at rest, morphine 1mg IV boluses will be administered, and repeated at the interval of 5 min until NRS is ≤ 3 for the first 24 h. Ondansetron 4 mg IV will be administered for persistent nausea (lasting >5 min) or vomiting.
In our institution, no step-down high dependency unit is available and patients will be transferred to the surgical ward after at least 2 h stay in the PACU.
Outcome parameters will be observed at PACU, 2, 4, 6, 8, 12 and 24 h after surgery.
Calculation of Sample Size
Sample size calculation was based on previous study with the use of intravenous lidocaine infusion for inguinal herniorrhaphy (Kang and Kim, 2011). Mean (SD) fentanyl consumption in the first 4-8 h between the lidocaine and placebo were 15.7 (6.3) and 21.4 (8.4) μg. Cohen d was used to calculate the effect size and was found to be 0.76.
Sample size was calculated using an online statistical calculator (G power® version 3.0.1). It was estimated that a sample size of 29 patients in each study group would achieve a power of 80% to detect an effect size of 0.76 in the primary outcome measure of opioid consumption, assuming a type I error of 0.05. Assuming 10% drop-outs during the study period, a total of 32 patients will taken for the study.
- Conditions
- Pain, Postoperative
- Being tested
- Lidocaine, Normal saline
- Keywords
- Totally Extraperitoneal Inguinal Hernioplasty, Lidocaine infusion, Postoperative opioid consumption
- Medical subject headings
- Pain, Postoperative
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LidocaineDrug
Also called Lignocaine, Loxicard
Lignocaine group will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
Normal salineDrug
Normal saline group will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
| Study group | Role | What they receive |
|---|---|---|
| Lidocaine | Experimental | Lignocaine group (Group A) will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation. Receives: Drug: Lidocaine |
| Normal saline | Placebo comparator | Normal saline group (Group B) will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation Receives: Drug: Normal saline |
What is being measured
The primary outcome is the main question the study is designed to answer.
Total morphine requirement during the first 24 h postoperatively
Measured: 24h
Secondary outcomes (9)
Pain at rest and with coughing or movement using the NRS scale
Measured: 24h
Time to first perception of pain
Measured: 24h
Incidence of postoperative nausea and vomiting (PONV) will be evaluated on a three-point ordinal scale.
0 = none, 1 = nausea, 2 = vomiting
Measured: 24h
Sedation score using five point scale
0=alert, 1=arouses to voice, 2=arouses with gentle tactile stimulation, 3 = arouses with vigorous tactile stimulation, 4 = lack of responsiveness
Measured: 24h
Time to first voiding.
Measured: 24h
Quality of Recovery based on QoR-40 questionnaire at 24 h of the surgery.
Measured: 24h
Patient satisfaction using Likert Satisfaction Scale at 24 h following surgery
1-Highly satisfied, 2-Satisfied, 3-Neutral, 4-Not satisfied, 5-Strongly dissatisfied
Measured: 24h
Other side effects such as light headedness, tinnitus, perioral numbness, arrythmia and pruritus will be documented.
Measured: 24h
Incidence of Chronic pain after TEP Repair
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Nov 2015 (estimated)
- Study startDec 2015
- Primary completionMar 2017
- Study completionMar 2017
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Pain, PostoperativeStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 64 participants (actual)
Sponsor and investigators
- Lead sponsor
- B.P. Koirala Institute of Health Sciences
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Dr. Anup Ghimire, B.P. Koirala Institute of Health Sciences
- Investigators
- Asish Subedi, MD, Study director, B.P. Koirala Institute of Health Sciences
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02601651
- Sponsor's protocol ID
- IRC/520/015
- Status last verified
- Sep 2018
- First submitted
- 9 Nov 2015
- Last updated
- 25 Sep 2018
- Results posted
- No
- Data monitoring committee
- Yes
Publications
Ghimire A, Subedi A, Bhattarai B, Sah BP. The effect of intraoperative lidocaine infusion on opioid consumption and pain after totally extraperitoneal laparoscopic inguinal hernioplasty: a randomized controlled trial. BMC Anesthesiol. 2020 Jun 3;20(1):137. doi: 10.1186/s12871-020-01054-2.
PubMed 32493276
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Effect of Perioperative Intravenous Lidocaine on Opioid Consumption and Pain After Laparoscopic Totally Extraperitoneal Inguinal Hernioplasty
- ClinicalTrials.gov ID
- NCT02601651
- Acronym / sponsor ID
- IRC/520/015
- Conditions
- Pain, Postoperative
- Keywords
- Totally Extraperitoneal Inguinal Hernioplasty, Lidocaine infusion, Postoperative opioid consumption
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 64 participants (actual)
- Lead sponsor
- B.P. Koirala Institute of Health SciencesUniversity, hospital or other
- Study start
- Dec 2015
- Primary completion
- Mar 2017 (actual)
- Study completion
- Mar 2017 (actual)
- First posted
- 10 Nov 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The primary objectives of this study is to access the effect of perioperative lidocaine infusion on total morphine requirement during the first 24 h postoperatively in patients who underwent laparoscopic totally extraperitoneal inguinal hernioplasty.
Detailed description
The use of intravenous lidocaine can be considered as a multimodal approach to pain relief. This method of analgesia has been associated with reductions in post-operative pain, analgesic consumption, nausea, vomiting and length of hospital stay in various surgeries (abdominal, spinal, thoracic surgery) including laparoscopic procedure .The primary reason for delayed patient recovery and longer hospital stays after surgery is postoperative pain and ileus .Opioids are the mainstay drug to treat pain in the postoperative period. However, nausea, vomiting, postoperative ileus and further delay in patient recovery will be exacerbated by opioid administration.
the higher inflammatory response is observed in the early postoperative phase following TEP surgery compared to the conventional shouldice repair. Therefore, laparoscopic repair of inguinal hernia should not be seen as less traumatic than the conventional approach.
Low-dose IV lidocaine (typically 1.5-3 mg/kg/h) is easy to administer, has well-established analgesic, anti-hyperalgesic, and anti-inflammatory effects, and excellent safety record . Because postoperative pain is to a large extent an inflammatory phenomenon, administration of systemic local anesthetics, which have inflammatory modulatory properties, could significantly reduce pain and therefore allow more rapid discharge. In addition, intravenous lidocaine is an effective modality for treating visceral pain.
Objectives
Primary : To access the effect of perioperative lidocaine infusion on total morphine requirement during the first 24 h postoperatively in patients who underwent laparoscopic TEP for inguinal hernioplasty
Secondary:
- Postoperative NRS Scores at rest and during movement (i.e. deep breathing, coughing) (at PACU, 2, 4, 6, 8, 12 and 24h)
- Time to first perception of pain in the postoperative period
- Incidence of post operative nausea and vomiting, shivering, and tinnitus during the first 24h
- Quality of Recovery based on QoR-40 questionnaire at 24 h of the surgery.
- Patient satisfaction at 24 h of the surgery.
- Incidence of Chronic pain after TEP Repair at 3 months.
RESEARCH HYPOTHESIS Perioperative intravenous lidocaine administration will not decrease opioid requirements and pain scores during the first 24 h after TEP for inguinal hernioplasty.
METHODOLOGY Written informed consent will be taken for the procedure from all the patients. A total of 64 male subjects of ASA PS I and II undergoing laparoscopic totally extraperitoneal inguinal hernia repair will be enrolled in the study. The study will be carried out according to the principles of the Declaration of Helsinki and following CONSORT guidelines.
After preoperative evaluation, all of the patients will be premedicated with oral diazepam (0.1-0.2 mg/kg; not exceeding > 10 mg) at the night before and 2 hour before surgery.In order to assess pain patients will be familiarized about the use of the Numeric Pain Rating Scale (NRS) (0-10 cm) where 0 is no pain and 10 is the worst imaginable excruciating pain. They will also be informed that they will be asked about the intensity of the pain using NRS score and the site of pain (incisional pain or groin pain) in the postoperative period.
During the study, both the patient and the investigator observing the outcome will be blinded about the assignment of patient group. In the preoperative holding area, the patients will be randomly assigned into any of two groups using computer generated random number. Details of group assignment and case number will be kept in a set of sealed opaque envelope. The anesthesia staff will open the envelope and prepare the intravenous solutions accordingly. The attending anesthesiologist who is unaware of the group allocated will follow the standard general anaesthesia protocol during the study.
In the operating room standard monitoring device will be attached to monitor and baseline heart rate, non-invasive blood pressure and oxygen saturation will be recorded. A peripheral vein will be cannulated for administration of IV fluid with 18 G cannula. Preoxygenation will be done with 100% oxygen for 3 min. Induction will be done with IV fentanyl 1.5 μg/kg, propofol 2-2.5 mg/kg till cessation of verbal response and tracheal intubation facilitated with vecuronium 0.1mg/kg IV.
At induction, lidocaine group (A group) patients will receive 1.5 mg/kg of lidocaine (Loxicard®, Neon pharmaceuticals, India) IV bolus followed by infusion of 2 mg/kg/h. The Normal Saline group (B group) will receive same volume IV bolus at induction followed by continuous infusion until the tracheal extubation.
Patients in both the group will receive preincisional infiltration in three trocar sites with 6 ml of 0.25% bupivacaine.
In all groups, anesthesia will be maintained with oxygen and isoflurane, adjusting the end-tidal concentration of isoflurane to maintain Mean Arterial Pressure(MAP) within 20% of baseline. IV fentanyl 0.5 μg/kg will be supplemented intraoperatively if MAP and heart rate increase by 20% from the baseline after ensuring adequate end tidal concentration of isoflurane ,muscle relaxation and targeted range of ETCO2. After observing curare notch in capnograph, supplemental vecuronium IV bolus doses will be given . Paracetamol 1 gm IV infusion will be started after induction and given over 15 min. Any episode of intraoperative hypotension (MAP lower than 65 mmHg) and bradycardia (heart rate < 50 bpm) will be treated with ephedrine 5 mg and atropine 0.4 mg IV respectively.
Standardized surgical procedure for the hernia as described for endoscopic TEP for inguinal hernia repair will be followed. Ketorolac 30 mg IV will be given at the end of surgery and continued at 8 h intervals postoperatively. On the completion of surgery, residual neuromuscular block will be reversed with neostigmine 0.05 mg/kg IV and glycopyrrolate 0.01 mg/kg IV. Following successful tracheal extubation, infusion of the lidocaine or saline will be stopped and the patient will be transferred to the postanesthesia care unit (PACU).
Postoperative Care and observation On arrival to the PACU, non-invasive blood pressure, heart rate, respiration, primary and secondary outcome variables will be monitored by the blinded investigator. Pain including its site will be assessed at rest and on deep breathing or coughing by NRS every 15 mins for the first 1 h and then at 2, 4, 6, 8, 12 and 24 h after surgery. If the NRS for pain is more than 3 at rest, morphine 1mg IV boluses will be administered, and repeated at the interval of 5 min until NRS is ≤ 3 for the first 24 h. Ondansetron 4 mg IV will be administered for persistent nausea (lasting >5 min) or vomiting.
In our institution, no step-down high dependency unit is available and patients will be transferred to the surgical ward after at least 2 h stay in the PACU.
Outcome parameters will be observed at PACU, 2, 4, 6, 8, 12 and 24 h after surgery.
Calculation of Sample Size
Sample size calculation was based on previous study with the use of intravenous lidocaine infusion for inguinal herniorrhaphy (Kang and Kim, 2011). Mean (SD) fentanyl consumption in the first 4-8 h between the lidocaine and placebo were 15.7 (6.3) and 21.4 (8.4) μg. Cohen d was used to calculate the effect size and was found to be 0.76.
Sample size was calculated using an online statistical calculator (G power® version 3.0.1). It was estimated that a sample size of 29 patients in each study group would achieve a power of 80% to detect an effect size of 0.76 in the primary outcome measure of opioid consumption, assuming a type I error of 0.05. Assuming 10% drop-outs during the study period, a total of 32 patients will taken for the study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Lidocaine | Experimental | Drug: LidocaineLignocaine group (Group A) will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation. |
| Normal saline | Placebo comparator | Drug: Normal salineNormal saline group (Group B) will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Male patients with American Society of Anaesthesiologists physical status (ASA PS) I and II of age 18 to 65 years
- Patients undergoing laparoscopic totally extraperitoneal repair for unilateral/bilateral inguinal hernia.
Key exclusion criteria (9 listed)
- Refusal to give consent.
- ASA physical status III or more.
- Inability to comprehend pain assessment score or severe mental impairment
- Patient who weighed < 40 kg or >100 kg
- Severe underlying cardiac rhythm disorder
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LidocaineAlso: Lignocaine, LoxicardLignocaine group will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation. | Drug | Lidocaine |
| Normal salineNormal saline group will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation | Drug | Normal saline |
Primary outcome
Total morphine requirement during the first 24 h postoperatively
Time frame: 24h
9 secondary outcomes
Pain at rest and with coughing or movement using the NRS scale
Time frame: 24h
Time to first perception of pain
Time frame: 24h
Incidence of postoperative nausea and vomiting (PONV) will be evaluated on a three-point ordinal scale.
Time frame: 24h
Sedation score using five point scale
Time frame: 24h
Time to first voiding.
Time frame: 24h
Quality of Recovery based on QoR-40 questionnaire at 24 h of the surgery.
Time frame: 24h
Patient satisfaction using Likert Satisfaction Scale at 24 h following surgery
Time frame: 24h
Other side effects such as light headedness, tinnitus, perioral numbness, arrythmia and pruritus will be documented.
Time frame: 24h
Incidence of Chronic pain after TEP Repair
Time frame: 3 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2018.
- Derived from this study: PubMed 32493276Ghimire A, Subedi A, Bhattarai B, Sah BP. The effect of intraoperative lidocaine infusion on opioid consumption and pain after totally extraperitoneal laparoscopic inguinal hernioplasty: a randomized controlled trial. BMC Anesthesiol. 2020 Jun 3;20(1):137. doi: 10.1186/s12871-020-01054-2.
Related trials for Pain, Postoperative
RecruitingPhase 4
ESP Blocks for Posterior Spinal Fusion
Postoperative Pain
Recruiting
Effect of Cryotherapeutic and Nanotherapeutic Sodium Hypochlorite on Post-Operative Endodontic Pain.
Symptomatic Irreversible Pulpitis, Symptomatic Apical Periodontitis
RecruitingPhase 2
REctus Sheath Trial
Acute Pain, Postoperative Pain, Acute
Not yet recruiting
Effect of Pectoral Nerve Block (PECS) Using Magnesium Sulfate Added to Dexamethasone on Quality of Recovery and Chronic Post-Mastectomy Pain
Breast Cancer, Postoperative Pain
Active, not recruitingPhase 4
Effect of Dexmedetomidine on Postoperative Pain in Spinal Anesthesia for Cesarean Section at Assuit University Hospital
Cesarean Section
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Asish Subedi, MD study director
B.P. Koirala Institute of Health Sciences
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Lidocaine and Normal saline in people with Pain, Postoperative, run by B.P. Koirala Institute of Health Sciences at 1 site in Nepal.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 25 Sep 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Nepal. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Total morphine requirement during the first 24 h postoperatively (time frame: 24h). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02601651, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2018.